Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04095273
Title Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | ESP | DEU


No variant requirements are available.